Ferring Pharmaceuticals, Inc.
🇺🇸United States
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Phase 1
Not yet recruiting
- Conditions
- Low-grade Upper Tract Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06668493
Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT06561958
- Locations
- 🇹🇭
Ferring Investigational Site, Bangkok, Thailand
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
Recruiting
- Conditions
- Infertility
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06545877
- Locations
- 🇯🇵
Ferring Investigational Site, Omitama, Ibaraki, Japan
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Phase 2
Recruiting
- Conditions
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06545955
- Locations
- 🇺🇸
Ferring Investigational Site, Myrtle Beach, South Carolina, United States
Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06515834
- Locations
- 🇯🇵
Ferring Investigational Site, Sumida-Ku, Tokyo, Japan
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
Phase 1
Recruiting
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06511791
- Locations
- 🇪🇸
Ferring Investigational Site, Valencia, Spain
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 3
Recruiting
- Conditions
- Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT06510374
- Locations
- 🇨🇦
Ferring Investigational Site, Burlington, Ontario, Canada
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation
Phase 1
Recruiting
- Conditions
- Fertility
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT06466486
- Locations
- 🇪🇸
Ferring Investigational Site, Valencia, Spain
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT06390111
- Locations
- 🇺🇸
Ferring Investigational Site, Atlanta, Georgia, United States
A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
Phase 1
Completed
- Conditions
- Inflammatory Gastrointestinal Diseases
- Interventions
- Drug: PlaceboDrug: Olamkicept Part BDrug: Olamkicept Part A
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT06298032
- Locations
- 🇩🇪
Ferring Investigational Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath